Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition

Background Flow cytometric (FC) detection of minimal residual disease (MRD) in multiple myeloma (MM) is prognostic and predictive of response to therapy. Therefore, standardization of FC MM MRD testing is vital to ensure better and uniform assessment of response to therapy and clinical prognosticati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cytometry. Part B, Clinical cytometry Clinical cytometry, 2016-01, Vol.90 (1), p.26-30
Hauptverfasser: Stetler-Stevenson, Maryalice, Paiva, Bruno, Stoolman, Lloyd, Lin, Pei, Jorgensen, Jeffrey L., Orfao, Alberto, Van Dongen, Jacques, Rawstron, Andy C.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 30
container_issue 1
container_start_page 26
container_title Cytometry. Part B, Clinical cytometry
container_volume 90
creator Stetler-Stevenson, Maryalice
Paiva, Bruno
Stoolman, Lloyd
Lin, Pei
Jorgensen, Jeffrey L.
Orfao, Alberto
Van Dongen, Jacques
Rawstron, Andy C.
description Background Flow cytometric (FC) detection of minimal residual disease (MRD) in multiple myeloma (MM) is prognostic and predictive of response to therapy. Therefore, standardization of FC MM MRD testing is vital to ensure better and uniform assessment of response to therapy and clinical prognostication. The International Clinical Cytometry Society and European Society for Clinical Cell Analysis, recognizing the need for standardized FC approaches, organized a working group to develop consensus guidelines on good clinical practice in FC MM MRD. Consensus guidelines are presented for specimen quality, staining process, reagent combinations, and the data acquisition process, all key factors in achieving high quality FC MM MRD testing. Methods A group of eight flow cytometrists currently performing FC testing in MM evaluated available literature on FC MM MRD testing. A document presenting best practice was developed and reviewed in successive rounds until consensus was reached. Results/Conclusion The consensus on best practice for detection of MRD in MM is that CD38, CD138, and CD45 are analyzed in combination with CD19, CD56, CD27, CD81, and CD117. Consensus guidelines on acceptable specimen quality, staining procedures, panel design, and data acquisition were developed. © 2015 International Clinical Cytometry Society
doi_str_mv 10.1002/cyto.b.21249
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7511978</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1760895920</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5949-f5ed9368c17cf523992f829774f31cf7dee23d8a7220f89b1123a4b0638034703</originalsourceid><addsrcrecordid>eNqNkUtv1DAURi1ERR-wY40isWHRTP2I43iDBCMolaoWUKGCBZYTXw9uE3tqJ8D8ezxMOwIWiJWv5HOPPvtD6DHBM4IxPepWY5i1M0poJe-hPcI5LSvJxf3tXMldtJ_SFcaMV7V4gHYpl1gQTPfQl3nwCXyaUrGYnIHeeUiFDbEYVtCHQReD827QfREhOTPlwbgEOkGR9LDs8zHqTPhFob0pjB51obubySU3uuAfoh2r-wSPbs8D9OH1q4v5m_L0_Phk_uK07HiOV1oORrK66YjoLKdMSmobKoWoLCOdFQaAMtNoQSm2jWwJoUxXLa5Zg1klMDtAzzfe5dQOYDrwY9S9WsYcPa5U0E79eePdV7UI35TghEjRZMGzW0EMNxOkUQ0uddD32kOYkiKi4bSigvL_QGvcSC7pOtbTv9CrMEWffyJTXNQNZ3gtPNxQXQwpRbDb3ASrdcdq3bFq1a-OM_7k97du4btSM1BtgO-uh9U_ZWr-6eL85Z233Ky5NMKP7ZqO16oWTHB1eXasxMfP-N2leKves59Re8Nc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1757685305</pqid></control><display><type>article</type><title>Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley Free Content</source><source>Alma/SFX Local Collection</source><creator>Stetler-Stevenson, Maryalice ; Paiva, Bruno ; Stoolman, Lloyd ; Lin, Pei ; Jorgensen, Jeffrey L. ; Orfao, Alberto ; Van Dongen, Jacques ; Rawstron, Andy C.</creator><creatorcontrib>Stetler-Stevenson, Maryalice ; Paiva, Bruno ; Stoolman, Lloyd ; Lin, Pei ; Jorgensen, Jeffrey L. ; Orfao, Alberto ; Van Dongen, Jacques ; Rawstron, Andy C.</creatorcontrib><description>Background Flow cytometric (FC) detection of minimal residual disease (MRD) in multiple myeloma (MM) is prognostic and predictive of response to therapy. Therefore, standardization of FC MM MRD testing is vital to ensure better and uniform assessment of response to therapy and clinical prognostication. The International Clinical Cytometry Society and European Society for Clinical Cell Analysis, recognizing the need for standardized FC approaches, organized a working group to develop consensus guidelines on good clinical practice in FC MM MRD. Consensus guidelines are presented for specimen quality, staining process, reagent combinations, and the data acquisition process, all key factors in achieving high quality FC MM MRD testing. Methods A group of eight flow cytometrists currently performing FC testing in MM evaluated available literature on FC MM MRD testing. A document presenting best practice was developed and reviewed in successive rounds until consensus was reached. Results/Conclusion The consensus on best practice for detection of MRD in MM is that CD38, CD138, and CD45 are analyzed in combination with CD19, CD56, CD27, CD81, and CD117. Consensus guidelines on acceptable specimen quality, staining procedures, panel design, and data acquisition were developed. © 2015 International Clinical Cytometry Society</description><identifier>ISSN: 1552-4949</identifier><identifier>EISSN: 1552-4957</identifier><identifier>DOI: 10.1002/cyto.b.21249</identifier><identifier>PMID: 25907102</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>Antigens, CD - analysis ; Antigens, CD - genetics ; Antigens, CD - immunology ; Antineoplastic Agents - therapeutic use ; Data Accuracy ; flow cytometry ; Flow Cytometry - standards ; Humans ; Immunophenotyping - standards ; minimal residual disease ; Multiple Myeloma - diagnosis ; Multiple Myeloma - drug therapy ; Multiple Myeloma - genetics ; Multiple Myeloma - immunology ; myeloma ; Neoplasm, Residual - diagnosis ; Neoplasm, Residual - drug therapy ; Neoplasm, Residual - genetics ; Neoplasm, Residual - immunology ; Plasma Cells - drug effects ; Plasma Cells - pathology ; Prognosis ; Remission Induction ; Specimen Handling - standards ; Staining and Labeling - standards</subject><ispartof>Cytometry. Part B, Clinical cytometry, 2016-01, Vol.90 (1), p.26-30</ispartof><rights>2015 International Clinical Cytometry Society</rights><rights>2015 International Clinical Cytometry Society.</rights><rights>2016 International Clinical Cytometry Society</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5949-f5ed9368c17cf523992f829774f31cf7dee23d8a7220f89b1123a4b0638034703</citedby><cites>FETCH-LOGICAL-c5949-f5ed9368c17cf523992f829774f31cf7dee23d8a7220f89b1123a4b0638034703</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcyto.b.21249$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcyto.b.21249$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,780,784,885,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25907102$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stetler-Stevenson, Maryalice</creatorcontrib><creatorcontrib>Paiva, Bruno</creatorcontrib><creatorcontrib>Stoolman, Lloyd</creatorcontrib><creatorcontrib>Lin, Pei</creatorcontrib><creatorcontrib>Jorgensen, Jeffrey L.</creatorcontrib><creatorcontrib>Orfao, Alberto</creatorcontrib><creatorcontrib>Van Dongen, Jacques</creatorcontrib><creatorcontrib>Rawstron, Andy C.</creatorcontrib><title>Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition</title><title>Cytometry. Part B, Clinical cytometry</title><addtitle>Cytometry</addtitle><description>Background Flow cytometric (FC) detection of minimal residual disease (MRD) in multiple myeloma (MM) is prognostic and predictive of response to therapy. Therefore, standardization of FC MM MRD testing is vital to ensure better and uniform assessment of response to therapy and clinical prognostication. The International Clinical Cytometry Society and European Society for Clinical Cell Analysis, recognizing the need for standardized FC approaches, organized a working group to develop consensus guidelines on good clinical practice in FC MM MRD. Consensus guidelines are presented for specimen quality, staining process, reagent combinations, and the data acquisition process, all key factors in achieving high quality FC MM MRD testing. Methods A group of eight flow cytometrists currently performing FC testing in MM evaluated available literature on FC MM MRD testing. A document presenting best practice was developed and reviewed in successive rounds until consensus was reached. Results/Conclusion The consensus on best practice for detection of MRD in MM is that CD38, CD138, and CD45 are analyzed in combination with CD19, CD56, CD27, CD81, and CD117. Consensus guidelines on acceptable specimen quality, staining procedures, panel design, and data acquisition were developed. © 2015 International Clinical Cytometry Society</description><subject>Antigens, CD - analysis</subject><subject>Antigens, CD - genetics</subject><subject>Antigens, CD - immunology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Data Accuracy</subject><subject>flow cytometry</subject><subject>Flow Cytometry - standards</subject><subject>Humans</subject><subject>Immunophenotyping - standards</subject><subject>minimal residual disease</subject><subject>Multiple Myeloma - diagnosis</subject><subject>Multiple Myeloma - drug therapy</subject><subject>Multiple Myeloma - genetics</subject><subject>Multiple Myeloma - immunology</subject><subject>myeloma</subject><subject>Neoplasm, Residual - diagnosis</subject><subject>Neoplasm, Residual - drug therapy</subject><subject>Neoplasm, Residual - genetics</subject><subject>Neoplasm, Residual - immunology</subject><subject>Plasma Cells - drug effects</subject><subject>Plasma Cells - pathology</subject><subject>Prognosis</subject><subject>Remission Induction</subject><subject>Specimen Handling - standards</subject><subject>Staining and Labeling - standards</subject><issn>1552-4949</issn><issn>1552-4957</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUtv1DAURi1ERR-wY40isWHRTP2I43iDBCMolaoWUKGCBZYTXw9uE3tqJ8D8ezxMOwIWiJWv5HOPPvtD6DHBM4IxPepWY5i1M0poJe-hPcI5LSvJxf3tXMldtJ_SFcaMV7V4gHYpl1gQTPfQl3nwCXyaUrGYnIHeeUiFDbEYVtCHQReD827QfREhOTPlwbgEOkGR9LDs8zHqTPhFob0pjB51obubySU3uuAfoh2r-wSPbs8D9OH1q4v5m_L0_Phk_uK07HiOV1oORrK66YjoLKdMSmobKoWoLCOdFQaAMtNoQSm2jWwJoUxXLa5Zg1klMDtAzzfe5dQOYDrwY9S9WsYcPa5U0E79eePdV7UI35TghEjRZMGzW0EMNxOkUQ0uddD32kOYkiKi4bSigvL_QGvcSC7pOtbTv9CrMEWffyJTXNQNZ3gtPNxQXQwpRbDb3ASrdcdq3bFq1a-OM_7k97du4btSM1BtgO-uh9U_ZWr-6eL85Z233Ky5NMKP7ZqO16oWTHB1eXasxMfP-N2leKves59Re8Nc</recordid><startdate>201601</startdate><enddate>201601</enddate><creator>Stetler-Stevenson, Maryalice</creator><creator>Paiva, Bruno</creator><creator>Stoolman, Lloyd</creator><creator>Lin, Pei</creator><creator>Jorgensen, Jeffrey L.</creator><creator>Orfao, Alberto</creator><creator>Van Dongen, Jacques</creator><creator>Rawstron, Andy C.</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201601</creationdate><title>Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition</title><author>Stetler-Stevenson, Maryalice ; Paiva, Bruno ; Stoolman, Lloyd ; Lin, Pei ; Jorgensen, Jeffrey L. ; Orfao, Alberto ; Van Dongen, Jacques ; Rawstron, Andy C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5949-f5ed9368c17cf523992f829774f31cf7dee23d8a7220f89b1123a4b0638034703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Antigens, CD - analysis</topic><topic>Antigens, CD - genetics</topic><topic>Antigens, CD - immunology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Data Accuracy</topic><topic>flow cytometry</topic><topic>Flow Cytometry - standards</topic><topic>Humans</topic><topic>Immunophenotyping - standards</topic><topic>minimal residual disease</topic><topic>Multiple Myeloma - diagnosis</topic><topic>Multiple Myeloma - drug therapy</topic><topic>Multiple Myeloma - genetics</topic><topic>Multiple Myeloma - immunology</topic><topic>myeloma</topic><topic>Neoplasm, Residual - diagnosis</topic><topic>Neoplasm, Residual - drug therapy</topic><topic>Neoplasm, Residual - genetics</topic><topic>Neoplasm, Residual - immunology</topic><topic>Plasma Cells - drug effects</topic><topic>Plasma Cells - pathology</topic><topic>Prognosis</topic><topic>Remission Induction</topic><topic>Specimen Handling - standards</topic><topic>Staining and Labeling - standards</topic><toplevel>online_resources</toplevel><creatorcontrib>Stetler-Stevenson, Maryalice</creatorcontrib><creatorcontrib>Paiva, Bruno</creatorcontrib><creatorcontrib>Stoolman, Lloyd</creatorcontrib><creatorcontrib>Lin, Pei</creatorcontrib><creatorcontrib>Jorgensen, Jeffrey L.</creatorcontrib><creatorcontrib>Orfao, Alberto</creatorcontrib><creatorcontrib>Van Dongen, Jacques</creatorcontrib><creatorcontrib>Rawstron, Andy C.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cytometry. Part B, Clinical cytometry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stetler-Stevenson, Maryalice</au><au>Paiva, Bruno</au><au>Stoolman, Lloyd</au><au>Lin, Pei</au><au>Jorgensen, Jeffrey L.</au><au>Orfao, Alberto</au><au>Van Dongen, Jacques</au><au>Rawstron, Andy C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition</atitle><jtitle>Cytometry. Part B, Clinical cytometry</jtitle><addtitle>Cytometry</addtitle><date>2016-01</date><risdate>2016</risdate><volume>90</volume><issue>1</issue><spage>26</spage><epage>30</epage><pages>26-30</pages><issn>1552-4949</issn><eissn>1552-4957</eissn><abstract>Background Flow cytometric (FC) detection of minimal residual disease (MRD) in multiple myeloma (MM) is prognostic and predictive of response to therapy. Therefore, standardization of FC MM MRD testing is vital to ensure better and uniform assessment of response to therapy and clinical prognostication. The International Clinical Cytometry Society and European Society for Clinical Cell Analysis, recognizing the need for standardized FC approaches, organized a working group to develop consensus guidelines on good clinical practice in FC MM MRD. Consensus guidelines are presented for specimen quality, staining process, reagent combinations, and the data acquisition process, all key factors in achieving high quality FC MM MRD testing. Methods A group of eight flow cytometrists currently performing FC testing in MM evaluated available literature on FC MM MRD testing. A document presenting best practice was developed and reviewed in successive rounds until consensus was reached. Results/Conclusion The consensus on best practice for detection of MRD in MM is that CD38, CD138, and CD45 are analyzed in combination with CD19, CD56, CD27, CD81, and CD117. Consensus guidelines on acceptable specimen quality, staining procedures, panel design, and data acquisition were developed. © 2015 International Clinical Cytometry Society</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>25907102</pmid><doi>10.1002/cyto.b.21249</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1552-4949
ispartof Cytometry. Part B, Clinical cytometry, 2016-01, Vol.90 (1), p.26-30
issn 1552-4949
1552-4957
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7511978
source MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley Free Content; Alma/SFX Local Collection
subjects Antigens, CD - analysis
Antigens, CD - genetics
Antigens, CD - immunology
Antineoplastic Agents - therapeutic use
Data Accuracy
flow cytometry
Flow Cytometry - standards
Humans
Immunophenotyping - standards
minimal residual disease
Multiple Myeloma - diagnosis
Multiple Myeloma - drug therapy
Multiple Myeloma - genetics
Multiple Myeloma - immunology
myeloma
Neoplasm, Residual - diagnosis
Neoplasm, Residual - drug therapy
Neoplasm, Residual - genetics
Neoplasm, Residual - immunology
Plasma Cells - drug effects
Plasma Cells - pathology
Prognosis
Remission Induction
Specimen Handling - standards
Staining and Labeling - standards
title Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T20%3A54%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Consensus%20guidelines%20for%20myeloma%20minimal%20residual%20disease%20sample%20staining%20and%20data%20acquisition&rft.jtitle=Cytometry.%20Part%20B,%20Clinical%20cytometry&rft.au=Stetler-Stevenson,%20Maryalice&rft.date=2016-01&rft.volume=90&rft.issue=1&rft.spage=26&rft.epage=30&rft.pages=26-30&rft.issn=1552-4949&rft.eissn=1552-4957&rft_id=info:doi/10.1002/cyto.b.21249&rft_dat=%3Cproquest_pubme%3E1760895920%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1757685305&rft_id=info:pmid/25907102&rfr_iscdi=true